Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methods
Not Applicable
- Conditions
- M81.00
- Registration Number
- DRKS00016907
- Lead Sponsor
- niv.Klinik für Nuklearmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 343
Inclusion Criteria
Study population: postmenopausal women between 50-59 years of age who receive aromatase inhibitor therapy due to hormone receptor-positive breast cancer and receive a bone density measurement within the first 3 months.
Control group: healthy, postmenopausal women between 50-59 years of age receiving bone density measurement.
Exclusion Criteria
Women younger than 50 or older than 59 years,
premenopausal women,
women who receive a specific antiosteoporotic therapy,
women who do not want to give informed consent,
women with a BMI>30kg/m² or a BMI <15 kg/m², because in these cases an exact TBS measurement is not possible.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All patients receive a structured questionnaire in which the FRAX criteria and the most important risk factors of osteoporosis are assessed. It will be investigated whether patients with breast cancer show a difference in bone density and thus in fracture risk compared to healthy women. The differences in FRAX score, TBS and TBS adjusted FRAX score are measured within a period of 3 months after the start of aromatase inhibitor therapy.
- Secondary Outcome Measures
Name Time Method